retatrutide clinical trial south korea Experimental Obesity Drug Also Effective in Treating Fatty Liver Eli Lilly obesity drug retatrutide

10.4049/jimmunol.1101682 J Immunol

Ideal for 1:1 Counseling: Use this handout to educate clients during MNT or GLP-1-focused sessions without reinventing the wheel

Manel Azzi, Email: [email protected]

Tirgaris cosmetic dermatology team

Prior authorizations, formulary changes, and high out-of-pocket costs can delay access or interrupt treatment

The Phase 2/3 LIFT-AD trial (NCT04488419), evaluating once-daily subcutaneous fosgonimeton 40 mg versus placebo in 312 participants with mild-to-moderate Alzheimers disease over 26 weeks, failed its primary endpoint (Global Statistical Test composite of ADAS-Cog11 and ADCS-ADL23) and its key secondary endpoints when results were announced in September 2024